A synthetic analog of alpha-melanocyte-stimulating hormone with comparative selectivity for MC1R — the narrower counterpart to Melanotan II, and a genuinely different compound.
Coming soon
You are on the list. We will email you if Melanotan I becomes available — and nothing else. Joining is not a medical request, and no prescription has been issued.
That did not go through. Check the address and try again.
Melanotan I is not offered through Promise yet, and may not be; the waitlist measures demand, and any prescription would still rest with a provider.
How it works once Melanotan I is available
Every treatment gets its own online clinical questionnaire — your history, medications, and goals.
A clinician reads your history and takes the time to get it right before anything is prescribed.
Compounded for your prescription and shipped cold-chain, with care-team check-ins after.
Melanotan I is easy to find online and hard to trust there. Promise works the way medicine is supposed to work — a clinician decides, a licensed pharmacy fills, and someone stays accountable to you.
Prescribed for you specifically, after a real look at your health history — never pulled off a shelf.
Your prescription is compounded for you by a licensed U.S. pharmacy — not a mystery vial from an unregulated website.
Temperature-safe shipping, follow-up check-ins, and a care team that answers — before and after your medication arrives.
Melanotan I is an analog of alpha-melanocyte-stimulating hormone that is comparatively selective for MC1R, the melanocortin receptor associated with melanin production in skin. That narrowness is what defines it.
The names differ by a numeral; the pharmacology does not line up. Melanotan II engages the melanocortin family broadly, including central sexual-function pathways. Reading about one tells you little about the other.
A compound acting on pigmented tissue makes moles and pigmented lesions a clinical matter. A licensed provider reviews every request, and here would want that history first.
Melanotan I is not available through Promise. There is no intake questionnaire for it, no price, and no date. It sits on a waitlist while our provider network works out whether it can be offered responsibly at all.
What this page can usefully do in the meantime is explain what the compound is — and, more to the point, how it differs from Melanotan II, a molecule that shares most of its name and very little of its pharmacology.
Melanotan I is a synthetic analog of alpha-melanocyte-stimulating hormone, a signaling peptide the body makes itself. Analogs of that hormone act as agonists at melanocortin receptors — a small family of receptors that sit in different tissues and take part in processes with little in common.
What sets Melanotan I apart within that family is selectivity. It is comparatively selective for MC1R, the melanocortin receptor associated with melanin production in skin. Research interest in it therefore centers on that one receptor rather than on the family as a whole, which makes it a narrower compound to reason about than a broad agonist is.
This is the thing worth leaving the page with. Melanotan II acts across the melanocortin family rather than picking one receptor, and that breadth includes receptors involved in central sexual-function pathways. That is why its nearest relative in our catalog is PT-141, and why, if it ever belongs anywhere here, it belongs under mood and libido.
Melanotan I does not have that profile. Its comparative selectivity for MC1R keeps it close to skin biology and away from those central pathways. The names differ by a single numeral, which makes the two look like editions of one product. They are not. A provider evaluating a request for one is weighing a genuinely different set of questions than for the other.
The placement follows from the pharmacology. Melanotan I is filed under anti-aging and longevity with GHK-Cu, because both are studied in the context of skin and connective tissue rather than mood, metabolism, or muscle. That grouping is descriptive. It says which biology a compound engages; it is not a statement about appearance and it is not a claim about outcomes.
A related analog, afamelanotide, has been studied clinically in erythropoietic protoporphyria, a rare inherited condition in which light exposure causes severe pain. That work is the most substantial clinical record anywhere in this molecule class, and it is reasonable background to know.
It is also a separately developed medicine, and its record does not carry over: Melanotan I as a compounded preparation is not FDA-approved, and we do not offer it for protoporphyria or for any other condition. Beyond that body of work, the human evidence around Melanotan I itself is limited, and a great deal of what circulates about it online is self-experimentation with material nobody verified.
Melanocortin agonists act on pigmented tissue. That is straightforward pharmacology, and it is the reason skin history is central here rather than incidental. Moles and other pigmented lesions can change, and a change in one is something a clinician examines rather than monitors from a distance. A provider considering any compound in this class would want that history up front and a plan for looking at skin afterward.
Two further things are worth stating flatly. Nothing described here is a sunscreen, and nothing described here substitutes for sun-protective behaviour — a compound acting on a pigmentation receptor does not make light exposure safe, and should never be treated as though it did. And identity matters: material bought outside a pharmacy channel has drawn health-authority warnings in several countries, which is a purity problem stacked on a pharmacological one.
Melanotan I is on a waitlist and nowhere else. If it were ever offered, it would arrive with an intake questionnaire written for it, a licensed provider reading that intake against your full history and your skin history in particular, and a prescription only where that provider judged it appropriate. Not everyone qualifies, and on a compound like this one, declining is an ordinary outcome rather than a surprising one.
Until then we have nothing to sell here, and no reason to pretend otherwise. If skin and connective tissue is what brought you, GHK-Cu is available now and reviewed the same way — a better place to keep a promise than a page with nothing behind it yet.
Melanotan I is a synthetic analog of alpha-melanocyte-stimulating hormone, a signaling peptide the body produces itself. Analogs of that hormone act as agonists at melanocortin receptors, a small family of receptors sitting in different tissues and taking part in unrelated processes. What distinguishes Melanotan I within that family is selectivity: it is comparatively selective for MC1R, the receptor associated with melanin production in skin. It is not available through Promise.
By receptor selectivity, which is the whole distinction. Melanotan II acts broadly across the melanocortin family, including receptors involved in central sexual-function pathways, which is why it sits nearer bremelanotide in our catalog. Melanotan I is comparatively selective for MC1R and stays much closer to skin biology. The names look like versions of one product and they are not; a person who has read about one has not read about the other, and a provider assessing a request for one is weighing a different set of questions.
No. Melanotan I is not FDA-approved. It would be prepared as a compounded medication, and compounded medications are not reviewed by the FDA for safety, effectiveness, or quality. A related analog, afamelanotide, has been studied clinically in a rare light-sensitivity condition called erythropoietic protoporphyria, but that is a separately developed medicine and its record does not transfer here. We do not offer this compound for protoporphyria or for any other condition.
There is no committed date, and it may not launch at all. Whether a melanocortin agonist can be offered responsibly is a clinical judgment for our provider network rather than a matter of demand, and that judgment has not been made. The waitlist tells us who is interested and nothing more; joining it reserves nothing, commits you to nothing, and does not commit us to building the treatment out.
Because a compound acting on pigmented tissue makes a person's skin history directly relevant, and no one can assess their own skin the way a clinician can. Moles and other pigmented lesions change, and any change in one is something a clinician examines rather than watches from a distance, both before treatment and afterward. It is also worth being plain about what this compound is not: it is not a sunscreen and not a substitute for sun-protective behaviour, and it is not offered for cosmetic or appearance-related use. A licensed provider reviews every request and prescribes only when treatment is appropriate.
Other Anti-Aging & Longevity options a provider may consider.
Anti-Aging & Longevity
A naturally occurring copper-binding tripeptide studied for skin remodeling and collagen-synthesis signaling, and one of the peptides in our KLOW blend.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.
Anti-Aging & Longevity
A synthetic tetrapeptide derived from a pineal-gland peptide, studied for telomerase activity and circadian signaling, and given as a short protocol course.
Requires an online medical evaluation. Prescribed only when a licensed provider determines it's appropriate.